Abilify (Aripiprazole).
What It Does, Side Effects, and What to Expect.

Aripiprazole (Abilify) is an atypical antipsychotic that has become one of the most prescribed psychiatric medications in the United States -- not primarily for schizophrenia, but as an add-on for depression when an antidepressant alone is not providing enough relief. Understanding how it differs from older antipsychotics, what akathisia is, and what to expect helps make a more informed decision about whether it fits your situation.

What Is Abilify?

Aripiprazole is classified as a third-generation or "atypical" antipsychotic, though its mechanism differs meaningfully from even other atypicals. Rather than simply blocking dopamine receptors (which older antipsychotics do), aripiprazole is a partial dopamine D2 agonist. It acts as a functional stabilizer: it blocks dopamine activity when dopamine is excessive, but activates dopamine pathways when activity is too low. This is why it tends to be more activating and less sedating than most other antipsychotics.

FDA-approved uses include:

• Schizophrenia (adults and adolescents 13+)
• Bipolar I disorder (manic and mixed episodes; maintenance)
• Major depressive disorder -- as adjunctive (add-on) therapy when antidepressants alone are insufficient
• Irritability associated with autistic disorder
• Tourette's disorder

Abilify as an Antidepressant Add-On

The most common reason adults in a general psychiatric practice encounter Abilify is as an augmentation strategy for depression. When a patient has been on a reasonable dose of an antidepressant for a sufficient time and has had only partial response -- improvement in some areas but persistent residual symptoms -- adding a low dose of aripiprazole (typically 2 to 5 mg, much lower than doses used for schizophrenia) can provide meaningful additional benefit.

This is well supported by clinical trial evidence. The mechanism is thought to involve dopaminergic enhancement in the prefrontal cortex (which SSRIs do not directly affect) and modulation of serotonin receptor activity.

Side Effects

• Akathisia -- the most important side effect to know about. Akathisia is an inner restlessness or compulsion to move that can be extremely distressing. It may present as an inability to sit still, pacing, or a sense of agitation that is hard to describe. It is dose-dependent and more common at higher doses. At the low doses used for depression augmentation it is less frequent but still possible. If you experience this, tell your prescriber -- dose reduction or switching to a different medication can resolve it.
• Nausea -- common early on
• Headache
• Insomnia -- more common than sedation, given the activating profile
• Dizziness
• Weight gain -- moderate; less than olanzapine (Zyprexa) or quetiapine (Seroquel) but still present for many patients. Metabolic monitoring (weight, lipids, glucose) is recommended with long-term use.

Long-Term Considerations

With long-term use of any antipsychotic, there is a risk of tardive dyskinesia (TD) -- involuntary repetitive movements, typically of the face, lips, or tongue. This risk is lower with aripiprazole than with older antipsychotics, but it is not zero. Periodic monitoring for early TD signs is recommended during ongoing treatment.

Metabolic effects (weight, blood sugar, cholesterol) should be monitored with laboratory tests during long-term treatment, particularly at higher doses.

Who Is Abilify a Good Fit For?

• Patients with partially-treated depression who have not achieved full remission on an antidepressant alone
• Bipolar disorder with depressive or mixed features
• Patients who need an antipsychotic with lower sedation burden than quetiapine or olanzapine
• Patients for whom weight gain with other augmentation agents (quetiapine, mirtazapine) is a significant concern